They are increasingly prescribed by providers because their effect on weight loss surpasses older weight loss pharmacotherapies.26,27 Between 2020 and 2023, the number of adolescents and young adults with GLP-1 RA dispensing increased by nearly 600%.28 The effect of weight loss through these recently approved, but increasingly used, drugs on nephrolithiasis risk in patients with known stone disease is not well understood. Here, GLP1R is linked to nephrolithiasis.